Relacorilant is a Corcept Therapeutics Inc program in cushing's syndrome (hypercortisolism). Its next catalyst is a Readout in Dec 2026. 2 FDA decisions on record below. Every date links its source.
All upcoming FDA decision dates on the 2026 PDUFA calendar
FDA approval tracked on pdufa.bio: platinum-resistant ovarian cancer (approved Mar 25, 2026). Earlier approvals may not be listed here; the FDA label is the full record. Indication under review: Cushing's syndrome (hypercortisolism). Sponsor: Corcept Therapeutics Inc (CORT). Review status: Corcept resubmitted the NDA for relacorilant in Cushing's syndrome in June 2026, after a December 2025 CRL, and states a PDUFA date of December 17, 2026 in its second-quarter release. Market-cap tier at the time we tracked it: Large. We track 4 catalyst events for this program: 2 upcoming and 2 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
| Fund | Shares | Value at quarter end | Filing |
|---|---|---|---|
| Perceptive Advisors | 398,385 | $34.6 million | filed August 14, 2026 |
13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.
The next tracked catalyst for Relacorilant is a Readout in Dec 2026.
On Mar 25, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.
In our records Relacorilant is FDA-approved for platinum-resistant ovarian cancer (approved Mar 25, 2026), and under review or in development for Cushing's syndrome (hypercortisolism). Other approved uses may not be tracked here; the FDA label is the full record.
Corcept Therapeutics Inc (CORT).
Yes. The FDA approved an application for Relacorilant on Mar 25, 2026; the decision page linked above carries the source.
FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.